Tri-Institutional TRAC Developmental Core

发展核心：发展核心的目标与总体三位一体的目标是一致的 结核病研究促进中心(TRI-I TRAC)：1)增加NIH资助的研究人员数量 开展结核病的基础、临床和转化研究；2)促进多学科的结核病研究 重点关注NIAID在结核病科学方面的五个优先事项。为此，发展核心将征集、审查和资助 一年50,000美元的开发项目奖，将帮助NIS和N2TB调查人员产生 为将来的R01或其他拨款申请提供的初步数据，通过协调对基础科学和 临床核心，以及结构化的指导和专业网络。这些活动加在一起，将 为NIS创建一条通往独立道路的培训。它将每年提供6个奖项，其中两个将是 每年由威尔·康奈尔大学的机构基金支持，以促进多样性。除了这一主要角色外， 发展科学核心还将通过以下方式加强国家创新系统在结核病研究方面的渠道： 本科生和研究生到现场；有助于提高毕业生的竞争地位 该领域博士后奖学金的学生；以及鼓励医生博士后研究员进入结核病 研究。因此，发展科学核心将使新的研究人员和 协作性翻译研究侧重于NIAID在结核病科学中的五个优先事项和最终目标 消除全世界结核病的发病率和死亡率。

The Developmental Core: The goals of the Developmental Core are the same as the overall Tri-Institutional TB Research Advancement Center (Tri-I TRAC): 1) To increase the number of NIH funded investigators conducting basic, clinical and translational research in TB and 2) To foster multidisciplinary TB research with a focus on NIAID’s five priorities for TB science. To do so, the Developmental Core will solicit, review and fund one year Developmental Project Awards of $50,000 that will help NIs and N2TB investigators generate preliminary data for future R01s or other grant applications by coordinating access to the Basic Science and Clinical Cores, along with structured mentorship and professional networking. Together, these activities will create a Training to Independence Pathway for NIs. It will provide 6 awards per year, two of which will be supported annually by Weill Cornell institutional funds to promote diversity. In addition to this primary role, the Developmental Science Core will also bolster the pipeline of NIs in TB research by: introducing undergraduates and graduate students to the field; helping to increase the competitive standing of graduate students for postdoctoral fellowships in the field; and encouraging physician post-doctoral fellows to enter TB research. The Developmental Science Core will thus enable a sustainable pipeline of new investigators and collaborative translational research focused on the five NIAID priorities in TB science and ultimate goal of ending morbidity and mortality from TB worldwide.